Compile Data Set for Download or QSAR
maximum 50k data
Found 44 with Last Name = 'wustman' and Initial = 'ba'
TargetBeta-galactosidase(Homo sapiens (Human))
Amicus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50358321(CHEMBL1922579 | CHEMBL1922581)
Affinity DataKi:  300nMAssay Description:Inhibition of human beta galactosidaseMore data for this Ligand-Target Pair
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175515(US9119845, 16)
Affinity DataKi:  440nM IC50:  1.07E+3nM EC50:  6.90E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238210(US9402837, 16)
Affinity DataKi:  440nM IC50:  1.07E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175523(US9119845, 24)
Affinity DataKi:  880nM IC50:  2.13E+3nM EC50:  3.05E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238214(US9402837, 24)
Affinity DataKi:  880nM IC50:  2.13E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175503(US9119845, 4)
Affinity DataKi:  1.66E+3nM IC50:  4.00E+3nM EC50:  6.30E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238200(US9402837, 4)
Affinity DataKi:  1.66E+3nM IC50:  4.00E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175504(US9119845, 5)
Affinity DataKi:  2.48E+3nM IC50:  5.99E+3nM EC50:  6.07E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238201(US9402837, 5)
Affinity DataKi:  2.48E+3nM IC50:  5.99E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175512(US9119845, 13)
Affinity DataKi:  3.11E+3nM IC50:  7.50E+3nM EC50:  2.20E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238208(US9402837, 13)
Affinity DataKi:  3.11E+3nM IC50:  7.50E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175511(US9119845, 12)
Affinity DataKi:  3.88E+3nM IC50:  9.36E+3nM EC50:  7.70E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238207(US9402837, 12)
Affinity DataKi:  3.88E+3nM IC50:  9.36E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175507(US9119845, 8)
Affinity DataKi:  5.26E+3nM IC50:  1.27E+4nM EC50:  1.16E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238204(US9402837, 8)
Affinity DataKi:  5.26E+3nM IC50:  1.27E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238213(US9402837, 23)
Affinity DataKi:  6.48E+3nM IC50:  1.56E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175522(US9119845, 23)
Affinity DataKi:  6.48E+3nM IC50:  1.56E+4nM EC50:  1.88E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238212(US9402837, 19)
Affinity DataKi:  8.02E+3nM IC50:  1.94E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175518(US9119845, 19)
Affinity DataKi:  8.02E+3nM IC50:  1.94E+4nM EC50:  3.50E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238216(US9402837, 18)
Affinity DataKi:  1.14E+4nM IC50:  2.76E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175517(US9119845, 18)
Affinity DataKi:  1.14E+4nM IC50:  2.76E+4nM EC50:  1.39E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238197(US9402837, 1)
Affinity DataKi:  1.48E+4nM IC50:  3.58E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175500(US9119845, 1)
Affinity DataKi:  1.48E+4nM IC50:  3.58E+4nM EC50:  6.59E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175502(US9119845, 3)
Affinity DataKi:  1.73E+4nM IC50:  4.17E+4nM EC50:  9.99E+3nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238199(US9402837, 3)
Affinity DataKi:  1.73E+4nM IC50:  4.17E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238215(US9402837, 25)
Affinity DataKi:  1.86E+4nM IC50:  4.50E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175524(US9119845, 25)
Affinity DataKi:  1.86E+4nM IC50:  4.50E+4nM EC50:  1.64E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238209(US9402837, 15)
Affinity DataKi:  2.04E+4nM IC50:  4.92E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175514(US9119845, 15)
Affinity DataKi:  2.04E+4nM IC50:  4.92E+4nM EC50:  6.83E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175506(US9119845, 7)
Affinity DataKi:  2.88E+4nM IC50:  6.95E+4nM EC50:  4.64E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238203(US9402837, 7)
Affinity DataKi:  2.88E+4nM IC50:  6.95E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238205(US9402837, 9)
Affinity DataKi:  5.37E+4nM IC50:  1.30E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175508(US9119845, 9)
Affinity DataKi:  5.37E+4nM IC50:  1.30E+5nM EC50:  1.45E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238202(US9402837, 6)
Affinity DataKi:  8.30E+4nM IC50:  2.00E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175505(US9119845, 6)
Affinity DataKi:  8.30E+4nM IC50:  2.00E+5nM EC50:  1.15E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238206(US9402837, 10)
Affinity DataKi:  1.12E+5nM IC50:  2.70E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175509(US9119845, 10)
Affinity DataKi:  1.12E+5nM IC50:  2.70E+5nM EC50:  7.06E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238211(US9402837, 17)
Affinity DataKi:  1.16E+5nM IC50:  2.80E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175516(US9119845, 17)
Affinity DataKi:  1.16E+5nM IC50:  2.80E+5nM EC50:  6.56E+4nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM238198(US9402837, 2)
Affinity DataKi:  4.06E+5nM IC50:  9.80E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Mus musculus (Mouse))
Amicus Therapeutics

US Patent
LigandPNGBDBM175501(US9119845, 2)
Affinity DataKi:  4.06E+5nM IC50:  9.80E+5nM EC50:  2.66E+5nMpH: 4.5Assay Description:To 2.5 μl of supernatant (in 96-well plates) was added 17.5 μl reaction buffer (citrate phosphate buffer, pH 4.5, no Triton X-100), and 50 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Amicus Therapeutics

US Patent
LigandPNGBDBM50182801((3R,4R,5R)-5-(Hydroxymethyl)piperidine-3,4-diol, 8...)
Affinity DataIC50:  59nMAssay Description:Inhibition of GCase assessed as 4-methylumbelliferone release assay after 30 mins by fluorimetryMore data for this Ligand-Target Pair
TargetPalmitoyl-protein thioesterase 1(Homo sapiens (Human))
Amicus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50429511(CHEMBL2332876)
Affinity DataIC50:  2.00E+3nMAssay Description:Inhibition of PPT1 in human fibroblast/lymphoblast cell lysate using fluorescent-based MUGSP as substrate after 1 to 3 hrsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPalmitoyl-protein thioesterase 1(Homo sapiens (Human))
Amicus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50429510(CHEMBL2332875)
Affinity DataIC50:  1.00E+4nMAssay Description:Inhibition of PPT1 (unknown origin) in cell lysates using fluorescent-based MUGSP as substrate after 1 to 3 hrsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed